Hypertension and Atrial Fibrillation: Any Change with the New Anticoagulants

Area of Science:

• Cardiology
• Internal Medicine

Background:

• Hypertension and atrial fibrillation (AF) are prevalent cardiovascular conditions, frequently coexisting and increasing with age.
• Hypertension is a significant risk factor for developing AF, driven by mechanisms like left ventricular changes and neurohormonal activation.
• AF is a major stroke risk factor, with risk amplified by concurrent hypertension.

Purpose of the Study:

• To review the intricate relationship between atrial fibrillation and hypertension.
• To explore pathophysiologic links contributing to AF onset in hypertensive individuals.
• To discuss the specific indications for novel anticoagulant therapies in preventing thromboembolic events in hypertensive patients with AF.

Main Methods:

• Literature review of existing studies on hypertension and atrial fibrillation.
• Analysis of pathophysiologic mechanisms linking hypertension to AF.
• Evaluation of current guidelines and evidence regarding antithrombotic treatment in this patient population.

Main Results:

• Hypertension remains the leading risk factor for AF development.
• Antihypertensive therapies can potentially decrease the incidence of new-onset AF.
• Hypertension significantly elevates stroke risk in patients with AF, necessitating risk stratification.

Conclusions:

• The interplay between hypertension and AF is complex, involving shared risk factors and pathophysiologic pathways.
• Effective management of hypertension is critical for AF prevention and stroke risk reduction.
• Novel anticoagulants offer promising strategies for thromboembolism prevention in hypertensive AF patients, requiring careful consideration of specific indications.